Study Summary
This trial is testing a new drug, AZD9833, to see if it can shrink tumors in women with a certain type of advanced breast cancer.
- Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 13 Secondary · Reporting Duration: Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
16 Treatment Groups
AZD9833 with abemaciclib dose escalation
1 of 16
AZD9833 monotherapy dose expansion
1 of 16
AZD9833 with palbociclib dose escalation
1 of 16
AZD9833 with palbociclib dose expansion
1 of 16
AZD9833 with abemaciclib (± anastrozole) dose escalation
1 of 16
AZD9833 with abemaciclib (± anastrozole)dose expansion
1 of 16
AZD9833 with ribociclib (± anastrozole) dose escalation
1 of 16
AZD9833 with ribociclib (± anastrozole) dose expansion
1 of 16
AZD9833 with anastrozole dose escalation
1 of 16
AZD9833 with anastrozole dose expansion
1 of 16
AZD9833 monotherapy dose escalation
1 of 16
AZD9833 with abemaciclib dose expansion
1 of 16
AZD9833 with capivasertib dose expansion
1 of 16
AZD9833 with everolimus dose expansion
1 of 16
AZD9833 with everolimus dose escalation
1 of 16
AZD9833 with capivasertib dose escalation
1 of 16
Experimental Treatment
403 Total Participants · 16 Treatment Groups
Primary Treatment: AZD9833 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 130 · Female Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this study recruiting participants at the present time?
"Affirmative. According to the information accessible on clinicaltrials.gov, this medical experiment is currently recruiting participants which was first advertised and posted on October 11th 2018. 402 patients are needed for 5 distinct healthcare facilities." - Anonymous Online Contributor
What medical conditions most commonly necessitate treatment with AZD9833?
"AZD9833 is regularly prescribed to treat kidney transplant rejection, and it has also been found successful in combating waldenstrom macroglobulinemia, lung cancer, and advanced carcinoid tumors." - Anonymous Online Contributor
Is AZD9833 a reliable option for individuals seeking medical assistance?
"Our team is of the opinion that AZD9833 ranks low on the safety scale, being a mere 1. This is because it has only recently entered Phase 1 trials and there is still limited data regarding its efficacy." - Anonymous Online Contributor
How many healthcare providers are administering this trial?
"Presently, the trial is running in 5 different medical centres which are located across Nashville, Salt Lake City and Sarasota as well as two other cities. In order to minimize travel time if you do decide to participate, please select the clinic nearest your residence." - Anonymous Online Contributor
Is the research only available to those who are of legal age?
"To be eligible for this trial, individuals must between 18 and 130 years of age." - Anonymous Online Contributor
What is the size of the cohort testing this therapeutic intervention?
"Absolutely, the facts on clinicaltrials.gov demonstrate that this research initiative is presently recruiting patients. The study was initially announced on October 11th 2018 and has been recently updated as of November 21st 2022. This medical trial requires 402 individuals to be recruited from 5 different locations." - Anonymous Online Contributor
Has AZD9833 previously undergone experimental testing?
"AZD9833 was first examined in 2008 at Sheba Medical Center, and 520 trials have been concluded since then. At present, 310 clinical studies are currently active with a large number centred around Nashville Tennessee." - Anonymous Online Contributor
What objectives is the study attempting to achieve?
"The primary goal of this 28-day clinical trial is to evaluate the amount of adverse events caused by treatment. Additional objectives include monitoring Progression Free Survival, Clinical Benefit Rate at 24 weeks, and Renal Clearance for AZD9833 through urine sample collection." - Anonymous Online Contributor
Who is eligible to participate in this medical experiment?
"This medical trial is looking for 402 individuals to join their cohort, who must be between ages 18 and 130 with a diagnosis of breast cancer." - Anonymous Online Contributor